Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (675) 675
science & technology (644) 644
life sciences & biomedicine (613) 613
male (427) 427
female (402) 402
middle aged (285) 285
oximes - adverse effects (273) 273
adult (253) 253
oximes - therapeutic use (247) 247
oximes (245) 245
animals (231) 231
biological and medical sciences (214) 214
medical sciences (207) 207
aged (194) 194
melanoma - drug therapy (183) 183
oximes - administration & dosage (180) 180
oximes - pharmacology (143) 143
pharmacology & pharmacy (143) 143
imidazoles - adverse effects (142) 142
melanoma (139) 139
proto-oncogene proteins b-raf - antagonists & inhibitors (126) 126
proto-oncogene proteins b-raf - genetics (117) 117
dermatology (115) 115
skin neoplasms - drug therapy (114) 114
toxicology (108) 108
imidazoles - administration & dosage (107) 107
oncology (99) 99
mutation (96) 96
imidazoles - therapeutic use (91) 91
pyridones - administration & dosage (81) 81
pyrimidinones - administration & dosage (81) 81
treatment outcome (81) 81
rats (80) 80
melanoma - genetics (79) 79
pyridones - adverse effects (78) 78
pyrimidinones - adverse effects (78) 78
technetium tc 99m exametazime (78) 78
skin neoplasms - pathology (77) 77
abridged index medicus (72) 72
adolescent (71) 71
organotechnetium compounds (70) 70
antineoplastic agents - adverse effects (69) 69
dabrafenib (69) 69
antineoplastic combined chemotherapy protocols - adverse effects (68) 68
pharmacology. drug treatments (68) 68
melanoma - pathology (67) 67
dose-response relationship, drug (65) 65
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
protein kinase inhibitors - adverse effects (64) 64
mice (63) 63
aged, 80 and over (61) 61
care and treatment (61) 61
double-blind method (61) 61
antineoplastic agents - therapeutic use (59) 59
time factors (56) 56
clinical trials as topic (54) 54
metastasis (53) 53
analysis (51) 51
melanoma - secondary (49) 49
research (49) 49
indoles - adverse effects (48) 48
oximes - chemistry (48) 48
sulfonamides - adverse effects (48) 48
fluvoxamine (46) 46
norgestrel - analogs & derivatives (46) 46
organophosphate poisoning (45) 45
risk factors (45) 45
poisoning (44) 44
acetylcholinesterase (43) 43
protein kinase inhibitors - therapeutic use (43) 43
skin neoplasms - genetics (43) 43
young adult (43) 43
drug therapy (42) 42
indoles - therapeutic use (42) 42
oximes - pharmacokinetics (42) 42
administration, oral (41) 41
physical sciences (41) 41
tomography, emission-computed, single-photon (41) 41
cancer (40) 40
health aspects (40) 40
neurosciences & neurology (40) 40
sulfonamides - therapeutic use (40) 40
cardiovascular system & cardiology (39) 39
chemistry (39) 39
general & internal medicine (39) 39
atropine (38) 38
oxime (38) 38
radionuclide imaging (38) 38
vemurafenib (38) 38
drug therapy, combination (37) 37
toxicity (37) 37
antidepressive agents - adverse effects (36) 36
protein kinase inhibitors - administration & dosage (36) 36
trametinib (36) 36
biochemistry & molecular biology (35) 35
medicine, general & internal (35) 35
pyridones - therapeutic use (35) 35
pyrimidinones - therapeutic use (35) 35
acetylcholinesterase - metabolism (33) 33
chemical and industrial products toxicology. toxic occupational diseases (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (875) 875
French (15) 15
German (11) 11
Japanese (7) 7
Italian (3) 3
Polish (3) 3
Spanish (2) 2
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
by Daud, Adil and Tsai, Katy
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
by Robert, Caroline and Karaszewska, Boguslawa and Schachter, Jacob and Rutkowski, Piotr and Mackiewicz, Andrzej and Stroiakovski, Daniil and Lichinitser, Michael and Dummer, Reinhard and Grange, Florent and Mortier, Laurent and Chiarion-Sileni, Vanna and Drucis, Kamil and Krajsova, Ivana and Hauschild, Axel and Lorigan, Paul and Wolter, Pascal and Long, Georgina V and Flaherty, Keith and Nathan, Paul and Ribas, Antoni and Martin, Anne-Marie and Sun, Peng and Crist, Wendy and Legos, Jeff and Rubin, Stephen D and Little, Shonda M and Schadendorf, Dirk
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
by Grob, Jean Jacques, Prof and Amonkar, Mayur M, PhD and Karaszewska, Boguslawa, MD and Schachter, Jacob, Prof and Dummer, Reinhard, Prof and Mackiewicz, Andrzej, Prof and Stroyakovskiy, Daniil, MD and Drucis, Kamil, MD and Grange, Florent, MD and Chiarion-Sileni, Vanna, MD and Rutkowski, Piotr, Prof and Lichinitser, Mikhail, Prof and Levchenko, Evgeny, MD and Wolter, Pascal, MD and Hauschild, Axel, Prof and Long, Georgina V, MD and Nathan, Paul, MD and Ribas, Antoni, Prof and Flaherty, Keith, MD and Sun, Peng, PhD and Legos, Jeffrey J, PhD and McDowell, Diane Opatt, MD and Mookerjee, Bijoyesh, MD and Schadendorf, Dirk, Prof and Robert, Caroline, MD
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
by Long, Georgina V and Hauschild, Axel and Santinami, Mario and Atkinson, Victoria and Mandalà, Mario and Chiarion-Sileni, Vanna and Larkin, James and Nyakas, Marta and Dutriaux, Caroline and Haydon, Andrew and Robert, Caroline and Mortier, Laurent and Schachter, Jacob and Schadendorf, Dirk and Lesimple, Thierry and Plummer, Ruth and Ji, Ran and Zhang, Pingkuan and Mookerjee, Bijoyesh and Legos, Jeff and Kefford, Richard and Dummer, Reinhard and Kirkwood, John M
The New England journal of medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
by Flaherty, Keith T and Infante, Jeffery R and Daud, Adil and Gonzalez, Rene and Kefford, Richard F and Sosman, Jeffrey and Hamid, Omid and Schuchter, Lynn and Cebon, Jonathan and Ibrahim, Nageatte and Kudchadkar, Ragini and Burris, Howard A and Falchook, Gerald and Algazi, Alain and Lewis, Karl and Long, Georgina V and Puzanov, Igor and Lebowitz, Peter and Singh, Ajay and Little, Shonda and Sun, Peng and Allred, Alicia and Ouellet, Daniele and Kim, Kevin B and Patel, Kiran and Weber, Jeffrey
The New England journal of medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | General aspects | Medical sciences | Dermatology | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
by Robert, Caroline and Grob, Jean J and Stroyakovskiy, Daniil and Karaszewska, Boguslawa and Hauschild, Axel and Levchenko, Evgeny and Chiarion Sileni, Vanna and Schachter, Jacob and Garbe, Claus and Bondarenko, Igor and Gogas, Helen and Mandalá, Mario and Haanen, John B.A.G and Lebbé, Celeste and Mackiewicz, Andrzej and Rutkowski, Piotr and Nathan, Paul D and Ribas, Antoni and Davies, Michael A and Flaherty, Keith T and Burgess, Paul and Tan, Monique and Gasal, Eduard and Voi, Maurizio and Schadendorf, Dirk and Long, Georgina V
The New England journal of medicine, ISSN 0028-4793, 08/2019, Volume 381, Issue 7, pp. 626 - 636
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Survival Rate | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Progression-Free Survival | Adolescent | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Drug therapy | Patient outcomes | Risk factors | Skin cancer | Dehydrogenases | MEK inhibitors | Melanoma | Clinical trials | Metastasis | Multivariate analysis | Survival | Patients | L-Lactate dehydrogenase | Metastases | Medical prognosis | Response rates | Biomarkers | Lactic acid | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
by Long, G. V and Flaherty, K. T and Stroyakovskiy, D and Gogas, H and Levchenko, E and de Braud, F and Larkin, J and Garbe, C and Jouary, T and Hauschild, A and Chiarion-Sileni, V and Lebbe, C and Mandala, M and Millward, M and Arance, A and Bondarenko, I and Haanen, J. B. A. G and Hansson, J and Utikal, J and Ferraresi, V and Mohr, P and Probachai, V and Schadendorf, D and Nathan, P and Robert, C and Ribas, A and Davies, M. A and Lane, S. R and Legos, J. J and Mookerjee, B and Grob, J. -J
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | trametinib | durable outcomes | metastatic | melanoma | BRAF | Original | dabrafenib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma
by Velter, C and Libenciuc, C and Routier, E and Mateus, C and Fahmy, J and Ghoufi, L and Lambotte, O and Not, A and Cauquil, C and Claveau, S and Claveau, J and Robert, C
European journal of cancer (1990), ISSN 0959-8049, 04/2019, Volume 111, pp. 8 - 11
Life Sciences & Biomedicine | Oncology | Science & Technology | Molecular Targeted Therapy - adverse effects | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Imidazoles - adverse effects | Middle Aged | Pyrimidinones - adverse effects | Azetidines - adverse effects | Male | Polyneuropathies - chemically induced | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Female | Aged | Vemurafenib - adverse effects | Molecular Targeted Therapy - methods | Pyridones - adverse effects | Neurotoxicity | Melanoma | Metastases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cutaneous adverse events in patients treated with BRAF inhibitor‐based therapies for metastatic melanoma for longer than 52 weeks
by Anforth, R and Carlos, G and Clements, A and Kefford, R and Fernandez‐Peñas, P
British journal of dermatology (1951), ISSN 0007-0963, 01/2015, Volume 172, Issue 1, pp. 239 - 243
Life Sciences & Biomedicine | Dermatology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Pyridones - administration & dosage | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Drug Eruptions - etiology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Melanoma - drug therapy | Sulfonamides - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Care and treatment | Squamous cell carcinoma | Melanoma | Metastasis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
by Hecht, M and Zimmer, L and Loquai, C and Weishaupt, C and Gutzmer, R and Schuster, B and Gleisner, S and Schulze, B and Goldinger, S.M and Berking, C and Forschner, A and Clemens, P and Grabenbauer, G and Müller-Brenne, T and Bauch, J and Eich, H.T and Grabbe, S and Schadendorf, D and Schuler, G and Keikavoussi, P and Semrau, S and Fietkau, R and Distel, L.V and Heinzerling, L
Annals of oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1238 - 1244
radiotherapy | vemurafenib | BRAF | radiation | dabrafenib | radiosensitization | Dabrafenib | Vemurafenib | Braf | Radiosensitization | Radiotherapy | Radiation | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Middle Aged | Radiation Tolerance | Melanoma - enzymology | Oximes - therapeutic use | Male | Protein Kinase Inhibitors - adverse effects | Radiosurgery - adverse effects | Whole-Body Irradiation - adverse effects | Feasibility Studies | Radiation-Sensitizing Agents - therapeutic use | Young Adult | Skin Neoplasms - enzymology | Time Factors | Aged, 80 and over | Adult | Female | Retrospective Studies | Imidazoles - therapeutic use | Proto-Oncogene Proteins B-raf - metabolism | Radiodermatitis - etiology | Skin Neoplasms - pathology | Chemoradiotherapy - methods | Skin Neoplasms - therapy | Europe | Imidazoles - adverse effects | Treatment Outcome | Radiodermatitis - prevention & control | Melanoma - pathology | Radiation-Sensitizing Agents - adverse effects | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Melanoma - therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights